Loading patent…
AssigneeBeth Israel Deaconess Medical Center, Inc.
InventorsVikas P. Sukhatme, Chunkong Barden Chan
Estimating the term…
Disclosed herein are methods for treating a vascular inflammatory disorder or endothelial cell disorder using inhibitor compounds that inhibit the expression or biological activity of Tie-1, Tie-1 endodomain, thrombin, VEGFR2, VEGFR2 endodomain, EphA2, and any of the cytokines or kinases that are upregulated by activation of Tie-1 or thrombin, as provided herein. Also disclosed are the use of combinations of inhibitor compounds or the use of an eNOS activator compound in combination with any one or more of the inhibitor compounds. Also disclosed are methods for inhibiting the pro-coagulant activity of thrombin using a Tie-1 or Tie-1 endodomain inhibitor compound or an EphA2 inhibitor compound. Methods for diagnosing and monitoring vascular inflammatory disorders or endothelial cell disorders that include the measurement of any of the polypeptides or nucleic acid molecules of the invention are also disclosed.
A method of inhibiting thrombin biological activity in a cell, said method comprising contacting said cell with a Tie-1 inhibitor compound in an amount and for a time sufficient to inhibit thrombin biological activity.
A method of inhibiting thrombin biological activity in a cell, said method comprising contacting said cell with an EphA2 inhibitor compound in an amount and for a time sufficient to inhibit thrombin biological activity.
A substantially pure VEGFR2 endodomain polypeptide comprising a polypeptide having a molecular weight of about 90 to 150 kDa, wherein the amino acid sequence of said polypeptide is substantially identical to the carboxy-terminus of the amino acid sequence of VEGF receptor 2, and wherein said VEGFR2 endodomain can be detected using an antibody directed to the carboxy-terminus of VEGF receptor 2.
Dependencies are inferred from the claim text.